common.study.topics.clinical

Secondary Prophylaxis of Clostridium Difficile Infection

common.study.values.description

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Oral Vancomycin

Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics

Placebo

Matched placebo twice a day prescribed for the duration of antibiotics

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

common.study.values.clinical-trial-id

NCT04000555

participant.views.study.view.id

dG6NJb